

EudraCT number: 2021-002076-39

Sponsor: F. Hoffmann-La Roche Ltd

Study: WC 42759

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Cerebral Edema Sponsor's decision to prematurely terminate the study due to operational considerations and not based on safety / efficacy concerns with balovaptan. At the time point of termination no participant was either screened or enrolled in the study. Therefore, there is no data to be reported.